Introduction {#Sec1}
============

Salivary excretion of some drugs has been reported previously as a good indicator for drug bioavailability, therapeutic drug monitoring, pharmacokinetics and also drug abuse. Saliva sampling is a simple, non-invasive and cheap method compared with plasma sampling, with no contamination risk \[[@CR1], [@CR2]\]. The rules of drug protein binding and membrane permeability on salivary excretion were previously investigated for several drugs, where a Salivary Excretion Classification System (SECS) was proposed as shown in Table [1](#Tab1){ref-type="table"} \[[@CR3]\]. High intestinal permeability corresponds to fraction absorption (*F*~a~) \>0.9, while high protein binding corresponds to low fraction unbound (fu) of \<0.1 \[[@CR4], [@CR5]\]. According to SECS, Class I drugs of high intestinal permeability and low protein binding, such as paracetamol, are subject to salivary excretion. Class II drugs of low permeability and low protein binding, such as metformin, are subject to salivary excretion since low permeability is counterbalanced by low protein binding. Class III drugs of high intestinal permeability and high protein binding, such as rusovastatin, are subject to salivary excretion since high protein binding is counterbalanced by high permeability. Class IV drugs of low intestinal permeability and high protein binding, such as montelukast, are not subject to salivary excretion \[[@CR3]\].Table 1Salivary excretion classification system (SECS) according to drug permeability (*P* ~eff~) and fraction unbound to plasma proteins (fu)ClassParameter*P* ~eff~fuSalivary excretionClass IHighHighYesClass IILowHighYesClass IIIHighLowYesClass IVLowLowNo

Objectives {#Sec2}
==========

The objective of this study is to investigate the robustness of using a non-invasive saliva sampling method instead of a plasma sampling method as a surrogate for bioequivalence of SECS class III drugs that are excreted in saliva, using rusovastatin as a model drug.

Methods {#Sec3}
=======

Study Design {#Sec4}
------------

Saliva pharmacokinetics under a fasted state, in 12 healthy human volunteers after signing informed consent, were compared with plasma pharmacokinetics in a two-way, cross-over design study with washout time between phases of 1 week. Medical history, vital signs, physical examination and laboratory safety test results showed no evidence of clinically significant deviation from normal medical condition as evaluated by the clinical investigator. The pilot bioequivalence study was conducted as per the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), Good Clinical Practice (GCP), and Helsinki declaration guidelines after Institutional Review Board (IRB) of Jordan Center of Pharmaceutical Research and Jordan FDA approvals.

An oral dose of 40 mg test product rusovastatin (Batch no. RD-04F13) or reference product (Batch no. KG115) with 240 ml of water was given after 10 h overnight fasting without dietary restrictions. Then resting saliva (without stimulation) and plasma samples were collected at 0, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 12, 24, 48 and truncated at 72 h during each study phase. Thorough rinsing of the mouth was done after dosing to avoid contamination of saliva samples with any drug residues.

Assay Methodology {#Sec5}
-----------------

All saliva and plasma samples were deep frozen until assayed by a validated liquid chromatography--mass spectrometry (LC--MS) assay method. Intra-day coefficient of variation (CV) was 14.26 %, inter-day accuracy range was 91.76--102.80 %, inter-day precision range was 2.21--13.41% and linear range was 0.5--40.00 ng/mL.

Data Analysis {#Sec6}
-------------

### Pharmacokinetic Parameters {#Sec7}

Individual pharmacokinetic parameters for drug concentration in both saliva and plasma samples were calculated by non-compartmental analysis (NCA) using Kinetica program V5. Pharmacokinetic parameters were area under the concentration curves to last collection time (AUC~*t*~), maximum measured concentration (*C*~max~) and time to maximum concentration (*T*~max~). Elimination parameters of half life, elimination rate constant and AUC~**∞**~ were not calculated since sampling was truncated at 72 h. Descriptive statistics and pharmacokinetic parameters were undertaken using Microsoft Excel.

### Dimensional and Correlation Analysis {#Sec8}

Saliva versus plasma concentrations up to median *T*~max~ values were correlated by linear regression using Microsoft Excel. Conversely, dimensional analysis was done on an individual basis, and then averages were statistically compared using a *t* test. Dimensional analysis offers the advantage of more clear comparisons since ratios are unitless. The following dimensionless ratios were calculated:$$\documentclass[12pt]{minimal}
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### Bioequivalence Analysis {#Sec9}

Analysis of variance (ANOVA), 90 % confidence intervals, and inter-subject and intra-subject variability estimates for primary pharmacokinetic parameters (AUC~*t*~ and *C*~max~) for test/reference ratios after logarithmic transformation were calculated by Kinetica program V5. The ANOVA model included the following sources of variations: phase, treatment, sequence and subject nested in sequence.

### Optimized Effective Intestinal Permeability {#Sec10}

Effective intestinal permeability (*P*~eff~) values were estimated by the Nelder--Mead algorithm of the parameter estimation module using the SimCYP program \[[@CR6]\]. The Nelder--Mead method, which is also called the downhill simplex method, is a commonly used nonlinear optimization algorithm. This involved searching for the best parameter values that produce plasma concentration that matches the actual plasma concentration at the same time. The objective function is the weighted sum of squared differences of observed and model predicted values. Polar surface area (PSA) was used first, using SimCYP, to predict an initial estimate of *P*~eff~.

Results and Discussion {#Sec11}
======================

Rusovastatin falls into SECS class III with high permeability (*F*~a~ = 1) and high protein binding (fu = 0.1) \[[@CR3]\]. It showed good salivary excretion with a correlation coefficient of 0.99 between saliva and plasma concentrations up to median *T*~max~ values of plasma profiles as shown in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}. Assuming a one-compartment linear model, the salivary excretion rate is dependent on plasma drug concentration. This explains the close behavior of the saliva and plasma profiles. This result is in agreement with a previous study with rusovastatin \[[@CR3]\]. Pharmacokinetic parameters in saliva and plasma for rusovastatin are summarized in Table [2](#Tab2){ref-type="table"}. AUC~*t*~ and*C*~max~ parameter values were lower in saliva as compared with plasma. However, *T*~max~ was longer in saliva, suggesting a lag time between plasma and saliva compartments due to drug distribution/redistribution processes in the body.Fig. 1Plasma and saliva of rusovastatin mean concentrations (ng/mL) after 40 mg oral doseFig. 2Correlation of saliva and plasma rusovastatin mean concentrationsTable 2Saliva and plasma mean (% CV) pharmacokinetic parameters after a 40-mg oral dose of rusovastatin tablet to 12 healthy volunteersParameterMatrixSaliva testSaliva referencePlasma testPlasma referenceAUC~*t*~ (ng/mL h)41.54 (98)48.78 (89)264.05 (41)281.92 (33)C~max~ (ng/mL)6.42 (141)6.78 (90)24.18 (42)22.74 (49)T~max~ (h)4.5 (39)4.25 (66)3.79 (13)3.54 (66)*AUC* ~*t*~ area under the concentration curves to last collection time, *C* ~max~ maximum measured concentration, *CV* coefficient of variation, *T* ~max~ time to maximum concentration

In addition, dimensional analysis results shown in Table [3](#Tab3){ref-type="table"} indicated lower bioavailability in saliva, yet no significant difference was observed between test and reference ratios. This can be related to the effect of high rusovastatin membrane effective permeability and high protein binding, leading to low saliva/plasma ratios. Moreover, AUC^\*^ and *C*~max~^\*^ values were in close agreement with *C*^\*^ values.Table 3Dimensional analysis values of pharmacokinetic parametersParameterTestReference*p* valueAUC\*0.170.170.92*C* ~max~\*0.250.350.56*T* ~max~\*1.231.470.15*C*\*0.170.180.46AUC^\*^ = saliva AUC~*t*~/plasma AUC~*t*~; *T* ~max~ ^\*^ = saliva *T* ~max~/plasma *T* ~max~; *C* ~max~ ^\*^ = saliva *C* ~max~/plasma *C* ~max~; *C* ^\* ^= saliva concentration/plasma concentration = *C* ~s~/*C* ~p~*AUC* ~*t*~ area under the concentration curves to last collection time, *C* ~max~ maximum measured concentration, *T* ~max~ time to maximum concentration

On the other hand, bioequivalence metrics and variability percentages for primary pharmacokinetic parameters were calculated in both saliva and plasma as shown in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}. The 90 % confidence intervals did not fall within the 80--125 % acceptance range as per the guideline (7), which is consistent with the high variability values observed in this pilot study. Hence, and due to higher inter-subject and intra-subject variability value in saliva as compared with plasma, more subjects are needed in the pivotal study using saliva matrix compared with plasma matrix. The optimum sample size was recalculated using Study Result program V1. Forty-six and 48 human subjects will be needed to account for 46.4 and 48 % intra-subject variability of *C*~max~ in plasma and saliva, respectively. ANOVA *p* values shown in Table [6](#Tab6){ref-type="table"} indicated insignificant differences (*p* \> 0.05) in all sources except subject (sequence) in saliva, which could be due to the small sample size used in this pilot study.Table 4Bioequivalence metrics of primary pharmacokinetic parameters after log transformationParameterSaliva^\*^Plasma^\*^AUC~*t*~81.8 (57.7--115.9)90 (72.7--111.4)*C* ~max~87.4 (61.3--124.8)107.5 (76.3--151.6)AUC~*t*~ area under the concentration curves to last collection time, *C* ~max~ maximum measured concentration\* Point estimate and 90 % confidence intervals (lower limit--upper limit)Table 5Saliva, plasma inter-subject and intra-subject variability values of primary pharmacokinetic parameters after log transformationParameterInter-subject CV %Intra-subject CV %AUC~*t*~13.7, 5.247.2, 28.8*C* ~max~32.8, 15.248.0, 46.4*AUC* ~*t*~ area under the concentration curves to last collection time, *C* ~max~ maximum measured concentrationTable 6ANOVA *p* values (AUC~*t*~, *C* ~max~) in plasma and salivaSourcePlasmaSalivaPhase0.245, 0.4820.885, 0.302Treatment0.391, 0.7090.320, 0.509Sequence0.355, 0.4690.178, 0.812Subject (sequence)0.075, 0.4860.002^\*^, 0.002^\*^*ANOVA* analysis of variance, *AUC* ~*t*~ area under the concentration curves to last collection time, *C* ~max~ maximum measured concentration\* Significant difference observed since *p* \< 0.05

Mean concentration profiles of the reference product were used to estimate the effective intestinal permeability values in plasma and saliva. Figure [3](#Fig3){ref-type="fig"} shows observed versus SimCYP-predicted concentration profiles with correlation coefficients of 0.85--0.87, indicating good fitting of observed concentrations. Optimized effective permeability coefficients were 68.17 and 68.30 × 10^−4^ cm/sec in plasma and saliva, respectively, which is in agreement with the previous value of 74.33 × 10^−4^ cm/sec \[[@CR3]\]. This confirms our previous finding that effective permeability and protein binding are major key factors in salivary excretion and our previous assumption that intestinal permeability is similar to salivary mucosal permeability \[[@CR3]\].Fig. 3Observed versus SimCYP-predicted rusovastatin concentrations of the reference product

From a regulatory point of view, the US FDA guidance for industry stated "The statutory definitions of BA and BE, expressed in terms of rate and extent of absorption of the active ingredient or moiety to the site of action, emphasize the use of pharmacokinetic measures in an accessible biological matrix such as blood, plasma, and/or serum to indicate release of the drug substance from the drug product into the systemic circulation" \[[@CR7]\]. Hence, from the data collected for drugs in SECS class III such as rusovastatin, there is a potential in bioavailability/bioequivalence (BA/BE) studies for saliva to be considered as a surrogate for plasma concentration. This line of research can help validate the newly proposed salivary excretion classification system. The use of saliva instead of plasma in such studies makes them non-invasive, easy and with a lower clinical burden.

Future Work {#Sec12}
===========

More research studies of candidate drugs that fall into classes I, II and III are needed in order to compare saliva versus plasma bioavailability and bioequivalence; and to demonstrate SECS robustness.
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